Back to search

University of Ioannina

Ανάπτυξη τεχνικών και βιοαντιδραστηρίων ανίχνευσης της τροπονίνης για τη διάγνωση καρδιαγγειακών παθήσεων

Abstract

dc:description

Troponin is a complex of three protein subunits (I, T, C), found in the skeletal (fast and slow contraction) and heart muscles and normally regulates their contraction. Among the three subunits, cardiac troponin I (cTnI) has the lowest homology to the corresponding skeletal isoforms, which implies increased myocardial specificity. It is also noteworthy that cTnI is more specific for the heart than other established biomarkers, such as CK-MB.When myocardial damage occurs, troponin is released from the myocyte cytosol into the bloodstream within two hours of the onset of symptoms (angina) and retained in the blood for about two weeks. The kinetics of cTnI, compared to other biomarkers, allow its rapid detection in patients' blood and better monitoring of its value as an indication of initial or possible subsequent damage. Therefore, cTnI is rightly the most significant biomarker in acute myocardial infarction diagnosis, as it can detect minor injuries that may be present in a high-risk patient with a vulnerable atherosclerotic plaque in the absence of myocardial necrosis.Given this, the researchers focused on detecting troponin and using it as a tool for earlydiagnosis of myocardial infarction to prevent and treat better the patient.The troponin test in clinical trials relies on the highly-sensitive ELISA technique. However, various factors like the specificity and sensitivity differences of the commercially available anti-troponin antibodies, the serine phosphorylation and cTnI conjugation to other molecules, and the presence of anti-cTnI autoantibodies (produced in response to the release of troponin in the blood) and interfering antibodies (heterophilic anti-animal antibodies) could lead to positive or negative false results. Hence, it is hard to classify individuals as candidates or not for acute myocardial infarction.The many different bio-reagents available have led to the need to set a cutoff detection limit with a coefficient of variation of less than 10% at a specific troponin concentration. This fact has gradually pushed to the development of higher analytical sensitivity tests, enabling better monitoring of the troponin value for the early diagnosis of a possible lesion. However, the high sensitivity of modern tests has been associated with reduced specificity. Except for patients, low levels of cTnI can be detected in other groups of the population, which do not have any damage (e.g. athletes), thus creating an additional diagnostic challenge.Modern clinical practices for troponin detection are mainly enzymatic immunoassays that detect cTnI with high sensitivity but a relatively long time and cost. Technological advances have allowed the development of non-enzymatic assays like electrochemical, paramagnetic, and surface plasmon. New technologies can reduce signal interferences, but they require bulky and expensive equipment and specially trained personnel. All these contribute to the increase in the final cost of the troponin test.Despite ongoing developments, there is considerable room for improvement in troponin tests, particularly in the standardization of the assays and elimination of interferences. New prospects also include the development of small, sensitive and portable biosensors (Point of care tests, POCTs), which allow the immediate detection of troponin by unskilled personnel, short analysis time and low cost.Given the above, the present dissertation aimed to develop enzymatic and non-enzymatic techniques, bio-reagents and materials for cardiac troponin I detection.For this purpose, a series of possible cTnI antigenic epitopes were synthesized. The epitopes were selected based on the homology, antigenicity, hydrophilicity, surface accessibility, flexibility, secondary structure, location, and frequency of well-known epitopes. Also, the antigen peptide carrier CPSOC(3,9-Acm) was synthesized, based on previous studies, which showed that this molecule could project the bound antigen epitopes and cause the production of high antibody titers, but also be useable as an adsorbent on an ELISA plate during immunoassays. The antigenic peptides (epitopes) were conjugated to the carrier via thioether bonds to form immunogenic macromolecules.Experimental animals (laying hens) were immunized with the conjugates, following two protocols that differed in immunogen concentration and the intervals between immunizations. The IgY antibodies were isolated from the collected immunized animals' eggs (following two different methods) and then purified by dialysis.Indirect ELISA assays were performed for monitoring IgY specificity for the immunogenic conjugates and the entire cTnI, while the antibodies titers of each immunization were compared. Also, the immunized hens were examined as per the duration that can produce specific antibodies. The stability of the antibodies, as a function of their storage time, was monitored, too.The antibodies were purified by affinity chromatography while their specificity for the cTnI19-31 epitope was being checked simultaneously. The material Seph@Ahx-cTnI19-31 was used for affinity chromatography, which resulted from the coupling of surface-modified (thiopropyl-group) sepharose beads with IAc-Ahx-cTnI19-31.Two ELISA sandwich-type assays were designed and performed to detect cTnI. In the one, Ac-12peptide was used to capture troponin, and in the other, for the same purpose, anticTnI IgG commercial antibodies were used, while in both cases, the antibodies produced against the mixture of the four immunogenic complexes were used as detection antibodies.Two SmMas (Smart Materials and Structure) were developed for detecting the cTnI. Based on the 12peptide (FYSHSFHENWPS) proposed to recognize cTnI, they were synthesized the following: 1) SiO2@12peptide, which consists of surface-modified silica nanoparticles coupled to 12peptide, and 2) TCDA@12peptide, which is composed of the 10,12-tricosadinoic acid conjugated to 12peptide.Afterwards, two non-enzymatic cTnI detection techniques were developed and tested in patient and healthy sera. In the first one, the material SiO2@12peptide was used and studied by thermogravimetry and FTIR spectroscopy. In the second one, the TCDA@12peptide was examined as per its colour change.Briefly, the results of the present dissertation showed that the immunized experimental animals produced high titer and specific antibodies against the immunogenic conjugates, which can detect cTnI. Also, the produced antibodies purified only by dialysis can be utilized without further purification to detect cTnI. Haptens can be used as materials for antibodies purification by affinity chromatography. The CPSOC(3,9Acm) carrier is useful in antibodies production, confirming previous relative studies. The isolated IgY antibodies from hen eggs are suitable tools for developing diagnostic tests and are stable for a long time. The materials SiO2@12peptide and TCDA@12peptide can be usable in the evolvent of cTnI detection assays.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Fotou, Evgenia
  • Φώτου, Ευγενία

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/51463

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Fotou, Evgenia; Φώτου, Ευγενία. Ανάπτυξη τεχνικών και βιοαντιδραστηρίων ανίχνευσης της τροπονίνης για τη διάγνωση καρδιαγγειακών παθήσεων. University of Ioannina, 2022. http://hdl.handle.net/10442/hedi/51463